APAC Healthcare Weekly (March 15) â Sino Bio, Hengrui, Astellas, Daiichi Sankyo, HK Inno, CSL
Couple of Chinese companies got clinical trials approvals for their respective drug candidates. Astellasâ Phase 3 trial failed to meet primary...
535 Views
APAC Healthcare Weekly (January 11) â Hengrui, Hansoh, InSilico Medicine, Takeda, Hanmi Pharm
Hegrui got nod for new drug and Hansohâs Ameile secured additional indication in China. InSilico entered $888M R&D collaboration. Takeda filed for...
295 Views
APAC Healthcare Weekly (December 21)âFosun Pharma, Hansoh, Daiichi Sankyo, Takeda, Hanmi, Max Health
Fosun Pharma is acquiring 53% stake in Green Valley. Hansoh inked exclusive license agreement with Glenmark Pharma. Daiichi Sankyoâs Enhertu got...
664 Views
APAC Healthcare Weekly (November 2) â Takeda, Eisai, Wuxi AppTec, Celltrion, CSL, PharmaEssentia
Takeda and Eisai witnessed clinical trials setback. Wuxi AppTec is selling China-based CRO subsidiaries. CSL is delaying demerger of CSL Seqirus....
886 Views
APAC Healthcare Weekly (October 19) â Hansoh, Leads Biolabs, Chugai, SanBio, Celltrion, Samsung Bio
Hansoh and Leads Biolabs bag global outlicensing deals. Chugaiâs partner Lilly announced positive P3 result for orforglipron. Celltrion launched...
1k Views